|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BRINP3 |
Gene summary for BRINP3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BRINP3 | Gene ID | 339479 |
| Gene name | BMP/retinoic acid inducible neural specific 3 | |
| Gene Alias | DBCCR1L | |
| Cytomap | 1q31.1 | |
| Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q76B58 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 339479 | BRINP3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.85e-39 | -1.05e+00 | 0.0155 |
| 339479 | BRINP3 | HTA11_2951_2000001011 | Human | Colorectum | AD | 8.04e-06 | -1.04e+00 | 0.0216 |
| 339479 | BRINP3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 8.43e-15 | -9.73e-01 | -0.0811 |
| 339479 | BRINP3 | HTA11_2112_2000001011 | Human | Colorectum | SER | 2.93e-04 | -9.66e-01 | -0.2196 |
| 339479 | BRINP3 | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.02e-10 | -7.97e-01 | -0.1207 |
| 339479 | BRINP3 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.17e-25 | -6.57e-01 | -0.1464 |
| 339479 | BRINP3 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.29e-20 | -6.60e-01 | -0.1001 |
| 339479 | BRINP3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.33e-24 | -9.12e-01 | -0.059 |
| 339479 | BRINP3 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.44e-05 | -9.12e-01 | -0.1706 |
| 339479 | BRINP3 | HTA11_5216_2000001011 | Human | Colorectum | SER | 6.06e-03 | -7.40e-01 | -0.1462 |
| 339479 | BRINP3 | HTA11_546_2000001011 | Human | Colorectum | AD | 4.48e-05 | -6.87e-01 | -0.0842 |
| 339479 | BRINP3 | HTA11_7862_2000001011 | Human | Colorectum | AD | 7.80e-08 | -5.33e-01 | -0.0179 |
| 339479 | BRINP3 | HTA11_866_3004761011 | Human | Colorectum | AD | 3.49e-36 | -1.06e+00 | 0.096 |
| 339479 | BRINP3 | HTA11_4255_2000001011 | Human | Colorectum | SER | 1.39e-02 | -8.53e-01 | 0.0446 |
| 339479 | BRINP3 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.14e-05 | -1.08e+00 | 0.0451 |
| 339479 | BRINP3 | HTA11_8622_2000001021 | Human | Colorectum | SER | 5.04e-09 | -1.03e+00 | 0.0528 |
| 339479 | BRINP3 | HTA11_6801_2000001011 | Human | Colorectum | SER | 3.29e-03 | -8.06e-01 | 0.0171 |
| 339479 | BRINP3 | HTA11_10711_2000001011 | Human | Colorectum | AD | 5.01e-17 | -9.51e-01 | 0.0338 |
| 339479 | BRINP3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 7.28e-62 | -1.06e+00 | 0.0674 |
| 339479 | BRINP3 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.47e-11 | -1.05e+00 | 0.0112 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
| GO:00073461 | Colorectum | MSS | regulation of mitotic cell cycle | 108/3467 | 457/18723 | 3.30e-03 | 2.50e-02 | 108 |
| GO:00073462 | Colorectum | FAP | regulation of mitotic cell cycle | 85/2622 | 457/18723 | 3.41e-03 | 2.48e-02 | 85 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BRINP3 | SNV | Missense_Mutation | c.1375N>T | p.Arg459Cys | p.R459C | Q76B58 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-A2-A259-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| BRINP3 | SNV | Missense_Mutation | c.1961C>A | p.Pro654His | p.P654H | Q76B58 | protein_coding | deleterious(0.04) | probably_damaging(0.936) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| BRINP3 | SNV | Missense_Mutation | novel | c.361N>A | p.Gln121Lys | p.Q121K | Q76B58 | protein_coding | deleterious(0.04) | probably_damaging(0.959) | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BRINP3 | SNV | Missense_Mutation | c.1449T>A | p.Asp483Glu | p.D483E | Q76B58 | protein_coding | tolerated(1) | benign(0) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| BRINP3 | SNV | Missense_Mutation | c.146C>T | p.Ser49Phe | p.S49F | Q76B58 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| BRINP3 | SNV | Missense_Mutation | rs146936488 | c.1520G>A | p.Arg507Gln | p.R507Q | Q76B58 | protein_coding | deleterious(0) | possibly_damaging(0.885) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BRINP3 | SNV | Missense_Mutation | c.405C>A | p.Phe135Leu | p.F135L | Q76B58 | protein_coding | tolerated(0.3) | benign(0.001) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BRINP3 | SNV | Missense_Mutation | c.1340N>T | p.Ser447Phe | p.S447F | Q76B58 | protein_coding | deleterious(0.03) | benign(0.135) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| BRINP3 | SNV | Missense_Mutation | c.352C>T | p.Pro118Ser | p.P118S | Q76B58 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BRINP3 | SNV | Missense_Mutation | c.1358C>T | p.Ala453Val | p.A453V | Q76B58 | protein_coding | deleterious(0.02) | benign(0.039) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |